Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.47 |
| ▸ | CHUK | O15111 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968190 | 1.00 | PARP1 (0.54) | PARP1JAK3IKBKBCHUKCSF1R | |
| SCHEMBL5330092 | 1.00 | PARP1 (0.54) | PARP1JAK3IKBKBCHUKCSF1R | |
| Hydrochloric Acid SCHEMBL28155977 | 0.98 | PARP1 (0.53) | PARP1JAK3IKBKBCHUKCSF1R | |
| Hydrochloric Acid SCHEMBL3669412 | 0.98 | PARP1 (0.53) | PARP1JAK3IKBKBCHUKCSF1R | |
| Hydrochloric Acid SCHEMBL28155968 | 0.98 | PARP1 (0.53) | PARP1JAK3IKBKBCHUKCSF1R | |
| SCHEMBL31227227 | 0.91 | CSF1R (0.57) | PARP1IKBKBCHUKCSF1RBTK | |
| SCHEMBL31227274 | 0.91 | CSF1R (0.57) | PARP1IKBKBCHUKCSF1RBTK | |
| SCHEMBL3649878 | 0.91 | CSF1R (0.57) | PARP1IKBKBCHUKCSF1RBTK | |
| SCHEMBL1006493 | 0.90 | IKBKB (0.53) | PARP1IKBKBCHUKSIRT2SLC6A2 | |
| Hydrochloric Acid SCHEMBL16445630 | 0.89 | CSF1R (0.56) | PARP1IKBKBCHUKCSF1RBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| EP-2766353-B1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2015-06-17 | — | — | EP | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| EP-2766353-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013053725-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013053725-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | CYP3A4, CYP2C19, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PARP1 400/4885JAK3 2001/4885IKBKB 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.